cilengitide has been researched along with Bone Loss, Osteoclastic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allen, JG; Babij, P; Fotsch, C | 1 |
| Cafforio, P; Felici, C; Resta, L; Rossi, R; Silvestris, F; Stucci, S; Tucci, M | 1 |
| Bäuerle, T; Berger, MR; Bretschi, M; Komljenovic, D; Merz, M; Semmler, W | 1 |
1 review(s) available for cilengitide and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Emerging targets in osteoporosis disease modification.
Topics: Animals; Biomarkers; Bone Density; Bone Resorption; Humans; Osteoporosis | 2010 |
2 other study(ies) available for cilengitide and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Cilengitide restrains the osteoclast-like bone resorbing activity of myeloma plasma cells.
Topics: Apoptosis; Bone Resorption; Cell Adhesion; Cell Proliferation; Female; Humans; Integrin alphaVbeta3; Male; Multiple Myeloma; Neoplasm Proteins; Osteoclasts; Plasma Cells; Receptors, Vitronectin; Snake Venoms; Tumor Cells, Cultured | 2016 |
Cilengitide inhibits metastatic bone colonization in a nude rat model.
Topics: Animals; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Disease Models, Animal; Female; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Osteoclasts; Rats; Rats, Nude; Snake Venoms; Xenograft Model Antitumor Assays | 2011 |